fda statement bpc-157 not approved In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like and Melanotan II. The move comes as demand for “ BPC-157: Experimental Peptide Creates Risk
Description
Published rodent in vivo studies have used intraperitoneal injection and oral (gavage) administration
In chronic stress HPA models (CRS 14 days): BPC-157 reduces corticosterone AUC 2228% (vagal-NTS-PVN CRH arc)
Comment on: 'Patients with unexplained neurological symptoms and signs should be screened for vitamin B12 deficiency regardless of haemoglobin levels'
The MIC amino complex plus B12, administered by a licensed clinician in about ten minutes
It is not licensed by the MHRA, is not available on NHS prescription, and has not been appraised by NICE for any indication
